|
| Tuesday, November 1, 2022 |
|
|
Led by Legend Capital, ClinBrain Completes Nearly CNY200 million Series C Round |
| Recently, the healthcare big data leader ClinBrain completed the Series C round of financing of nearly CNY200 million, led by Legend Capital. more info >> |
|
|
Led by Legend Capital, Easy-Flow Raises Tens of Millions of CNY in Angel Round |
| Shanghai Easy-Flow ("Easy-Flow") recently completed its Angel financing round by raising tens of millions of CNY, led by Legend Capital. The fresh capital will be used for the R&D of Easy-Flow's peripheral intervention pipeline. more info >> |
|
| Thursday, October 20, 2022 |
|
|
Co-Led by Legend Capital, Top Gene Delivery Enterprise VectorBuilder Secures CNY410mn in Series C Round |
| VectorBuilder Biotechnology (Guangzhou) Co., Ltd. (hereinafter referred to as "VectorBuilder"), a top gene delivery enterprise, recently announced the completion of its Series C round with CNY410 million, co-led by Legend Capital. more info >> |
|
| Sunday, September 25, 2022 |
|
|
GalaxySpace Completes a New Financing Round with Legend Capital Re-upped |
| GalaxySpace, a Chinese commercial aerospace company, recently completed its latest financing round with a post-investment valuation of approximately RMB11 billion. more info >> |
|
|
Leadrive Technology Completes Series C Financing, Legend Capital Re-upped |
| Leadrive Technology, a leading supplier of power semiconductor and motor control solutions for new energy vehicles, recently announced its completion of the series C financing. As the existing shareholder, Legend Capital continued to support this round of financing. more info >> |
|
| Friday, September 2, 2022 |
|
|
Legend Capital: The Logic of Technology Investment Has Changed |
| Legend Capital recently announced that it made its 100th IPO following the listing of its AI medical portfolio company Lunit on the KOSDAQ market on 21 July 2022. more info >> |
|
| Friday, August 19, 2022 |
|
|
Led by Legend Capital, Multi-omics-leading Enterprise APTBIO Closes Series B with Hundreds of Millions of CNY |
| Shanghai Applied Protein Technology Co., Ltd. ("APTBIO"), a leading enterprise focused on mass spectrometry-based multi-omics applied to precision medicine, recently announced the completion of its Series B with hundreds of millions of CNY, which is led by Legend Capital. more info >> |
|
| Monday, August 15, 2022 |
|
|
Legend Capital Portfolio: China-leading CRO Enterprise R&G Pharmastudies Listed on the ChiNext Market Successfully |
| On August 2, 2022, R&G Pharmastudies Co., Ltd. (stock code: 301333.SZ), a China-leading CRO enterprise invested by Legend Capital, was successfully listed on the ChiNext of Shenzhen Stock Exchange. more info >> |
|
| Tuesday, August 9, 2022 |
|
|
Legend Capital Super Antibiotic Portfolio Company: Scarce Enterprise MicuRx Pharmaceuticals is Listed on the STAR Market Successfully |
| On August 5, 2022, Legend Capital portfolio company MicuRx Pharmaceuticals, a scarce enterprise in super antibiotic, was successfully listed on the STAR Market. more info >> |
|
| Monday, August 8, 2022 |
|
|
New Power to Legend Capital Carbon Neutral Investment Portfolio: Ruicycle Raises Over RMB 300 Million from Series B |
| Shenzhen Ruicycle Environmental Protection Technology Co., Ltd (also known as Hengchuang Ruineng), a battery recycling company, recently accomplished the B round of fundraising with over RMB 300 million, which is backed by Legend Capital. more info >> |
|
|
|
